becom
routin
compon
medicin
problem
consist
potenc
avail
suppli
puriti
safeti
common
nevertheless
effect
imperfect
vaccin
lead
eventu
global
erad
smallpox
inspir
develop
product
program
immun
sever
diseas
human
anim
loui
pasteur
first
use
term
vaccin
immunogen
direct
diseas
besid
smallpox
pasteur
direct
mani
investig
demonstr
feasibl
attenu
inactiv
microb
studi
fowl
cholera
anthrax
led
concept
chemic
inactiv
mean
reduc
virul
microorgan
studi
erysipela
rabi
explor
serial
passag
anim
lapin
passag
rabbit
anim
deriv
tissu
altern
strategi
reduc
elimin
virul
thu
virul
infecti
microb
could
complet
partial
reduc
studi
led
eventu
success
control
anthrax
rabi
particular
work
salmon
smith
clearli
demonstr
microb
could
complet
inactiv
kill
develop
eventu
led
success
immun
program
typhoid
fever
tuberculosi
rinderpest
foot
mouth
diseas
fmd
attenu
inactiv
principl
extend
microbi
toxin
work
gaston
ramon
pasteur
institut
tetanu
toxoid
develop
heat
formalin
inactiv
toxin
form
anatoxin
also
enhanc
efficaci
provid
absorb
toxoid
aluminum
hydroxid
provid
adjuv
effect
process
formul
improv
develop
refin
earli
twentieth
centuri
first
product
equin
sera
antidiphtheria
antitetanu
toxinneutr
antibodi
prophylact
use
modern
era
vaccin
use
basic
technolog
still
mainstay
vaccin
product
howev
new
gener
recombin
nucleic
acid
subunit
vaccin
becom
avail
remark
principl
development
research
registr
manufactur
still
follow
techniqu
grand
heritag
earli
year
modern
era
vaccin
product
infect
tissu
often
use
sourc
microbi
antigen
grind
inactiv
typic
formaldehyd
solut
subsequ
filtrat
clarif
often
vaccin
produc
region
research
institut
industri
process
began
largescal
control
process
use
produc
fmd
antigen
germani
waldmann
colleagu
develop
first
primari
subsequ
clean
cell
line
occur
develop
highvolum
roller
bottl
method
later
largescal
bioreactor
made
possibl
product
million
dose
vaccin
product
maintain
secur
close
system
enhanc
secur
environ
well
technic
staff
like
manner
improv
inactiv
technolog
cycliz
binari
ethyleneimin
purif
concentr
antigen
storag
bulk
antigen
improv
aluminum
gel
oil
suspens
adjuv
formul
polyval
antigen
critic
achiev
steadi
advanc
vaccinolog
technic
advanc
employ
industri
independ
collabor
effort
numer
government
author
creat
regulatori
framework
establish
regul
guidelin
registr
new
biolog
well
consist
manufactur
pure
safe
potent
vaccin
regul
releas
lot
vaccin
test
ensur
consist
formul
characterist
potenc
immunolog
strength
safeti
puriti
steril
freedom
contamin
extran
biolog
agent
develop
good
manufactur
practic
guidelin
master
seed
master
cell
stock
concept
ensur
consist
manufactur
vaccin
provid
consist
immunogen
efficaci
veterinari
clinician
therefor
may
use
confid
approv
vaccin
recommend
manufactur
achiev
anticip
clinic
outcom
protect
vaccin
manufactur
process
improv
regard
consist
biolog
activ
robust
effici
routin
clinic
use
vaccin
becam
practic
econom
doubt
widespread
use
efficaci
vaccin
associ
global
erad
smallpox
human
region
control
fmd
rabi
routin
use
process
immunoglobulin
usual
form
process
hors
serum
preced
use
vaccin
although
passiv
protect
immunoglobulin
still
employ
particularli
rabi
tetanu
post
exposur
prophylaxi
advantag
activ
immun
immunolog
memori
reduc
risk
infect
significantli
reduc
use
passiv
immun
veterinarian
commonli
use
rabi
vaccin
brain
tissu
origin
dog
princip
biolog
product
use
practic
time
rabi
vaccin
viabil
canin
distemperhepat
viru
vaccin
antisera
hog
cholera
erysipela
vaccin
antisera
leptospirosi
bacterin
clostridi
toxoid
fig
develop
manufactur
capac
increas
time
vaccin
companion
anim
expand
includ
rabi
cat
felin
herpesviru
parvoviru
cat
dog
felin
caliciviru
tabl
describ
type
vaccin
current
avail
companion
anim
practition
region
world
http
wwwaphisusdagovanimalhealthvetbiolog
vblicensedproductsshtml
vaccin
includ
tradit
inactiv
antigen
formul
multipl
attenu
agent
new
technolog
poxvector
vaccin
defin
subunit
vaccin
nucleic
acid
vaccin
see
tabl
term
vaccin
use
describ
mani
therapeut
prophylact
formul
product
stimul
activ
immun
vaccin
anim
discuss
focus
vaccin
associ
infecti
diseas
routin
clinic
use
vaccin
usual
includ
immun
puppi
kitten
approxim
interv
maternalderiv
antibodi
decreas
noninterf
titer
immun
seri
usual
administ
fourth
week
life
puppi
kitten
associ
unusu
risk
may
vaccin
younger
age
frequent
interv
rabi
vaccin
usual
first
given
month
age
common
efficaci
practic
provid
booster
dose
year
age
vaccin
immun
practic
provid
solid
durat
immun
least
year
longer
case
gener
recommend
world
small
anim
veterinari
associ
vaccin
everi
third
year
initi
immun
seri
recommend
consist
product
label
guidelin
initi
immun
guidelin
deriv
initi
registr
immunogen
efficaci
studi
individu
vaccin
product
efficaci
studi
defin
minimum
immunolog
strength
vaccin
potenc
must
present
vaccin
lot
goe
date
type
studi
also
defin
minimum
age
anim
success
immun
well
specif
initi
booster
immun
regimen
part
code
feder
regul
vaccin
veterinari
medicin
becom
clear
mani
vaccin
provid
effect
longterm
immun
extend
period
time
past
decad
cumul
evid
extend
durat
immun
provid
support
booster
interv
vaccin
dog
cat
howev
describ
tabl
rel
efficaci
vaccin
less
ideal
ideal
immun
would
protect
clinic
diseas
morbid
mortal
also
block
infectionreplicationspread
progress
infecti
agent
vaccin
achiev
degre
protect
howev
may
reduc
morbid
andor
mortal
without
gener
steril
immun
base
clinic
microbiolog
outcom
efficaci
studi
challeng
immun
variou
degre
protect
may
achiev
therefor
claim
unit
state
depart
agricultur
usda
recogn
differ
hierarchi
efficaci
claim
may
allow
vaccin
base
outcom
efficaci
studi
box
degre
efficaci
claim
structur
usual
deriv
direct
investig
efficaci
challeng
immun
studi
respect
host
anim
speci
vaccin
nonvaccin
anim
challeng
fulli
virul
organ
degre
protect
efficaci
determin
control
set
classic
studi
adequ
establish
efficaci
vaccin
alway
suffici
estim
field
effect
vaccin
word
abil
vaccin
control
diseas
field
effect
control
infecti
diseas
result
reduc
incid
preval
would
true
clinic
diseas
also
infect
spread
infecti
agent
clear
use
efficaci
product
reduc
incid
rabi
particularli
dog
immun
dog
reduc
incid
canin
rabi
essenti
nil
unit
state
western
europ
rabi
immun
program
countri
effect
manufactur
rabi
vaccin
dog
cat
switch
master
seed
canin
street
strain
viru
type
terrestri
rabi
bat
strain
instanc
protect
signific
current
threat
region
vaccin
also
greatli
reduc
incid
canin
distemp
canin
parvoviru
infecti
canin
hepat
felin
panleukopenia
felin
herp
viru
infect
well
diseas
diseas
occur
usual
issu
vaccin
dose
complianc
vaccin
sick
immunocompromis
anim
exposur
wildlif
problem
associ
vaccin
handl
andor
administr
situat
vaccin
provid
prevent
infect
concurr
infect
may
exist
vaccin
failur
therefor
common
often
issu
typespecif
protect
instanc
clear
avail
vaccin
protect
cat
type
caliciviru
infect
continu
vigil
requir
ensur
continu
protect
anim
face
potenti
newli
evolv
emerg
pathogen
eg
rabi
lyssavirus
canin
distemp
parvovirus
felin
caliciviru
vaccin
use
veterinari
medicin
gener
fall
categori
inactiv
vaccin
antigen
typic
combin
adjuv
attenu
live
vaccin
recombin
technolog
vaccin
may
includ
subunit
antigen
genet
engin
organ
practic
combin
multival
vaccin
may
employ
approach
technolog
use
success
approach
inher
advantag
disadvantag
protect
mechan
associ
vaccin
also
becom
clearer
histor
common
correl
immun
deriv
vaccin
measur
antibodi
respons
antibodi
sever
function
includ
facilit
opson
complementmedi
cellular
lysi
neutralizationblock
adher
replic
facilit
cytotox
cell
howev
matur
welldifferenti
immun
respons
consequ
cumul
regul
interact
phagocyt
cell
antigenpres
cell
b
lymphocyt
therefor
welldifferenti
antibodi
respons
isotyp
switch
affin
matur
high
avid
memori
requir
effect
initi
stimul
involv
dendrit
cell
expans
regulatori
lymphocyt
claim
intend
prevent
diseas
may
made
product
shown
highli
effect
prevent
clinic
diseas
vaccin
challeng
anim
entir
interv
estim
efficaci
must
least
label
statement
prevent
diseas
due
specif
microorgan
may
use
aid
diseas
prevent
claim
intend
aid
diseas
prevent
may
made
product
shown
prevent
diseas
vaccin
challeng
anim
clinic
signific
amount
may
less
requir
support
claim
diseas
prevent
section
label
statement
aid
prevent
diseas
due
specif
microorgan
may
use
aid
diseas
control
claim
intend
aid
diseas
control
may
made
product
shown
allevi
diseas
sever
reduc
diseas
durat
delay
diseas
onset
label
statement
aid
control
diseas
due
specif
microorgan
similar
one
state
product
particular
action
may
use
like
b
lymphocyt
stimul
phase
follow
phase
differenti
effectormemori
cell
b
cell
plasma
cell
respect
natur
pathogenesi
mani
infecti
agent
adapt
immun
respons
vaccin
often
block
interfer
specif
segment
infect
process
instanc
antibodymedi
neutral
rabi
viru
extracellular
space
inhibit
transmiss
neuron
subsequ
axon
progress
viru
central
nervou
system
case
presenc
preform
neutral
antibodi
critic
protect
summari
protect
characterist
immun
respons
vaccin
potenti
correl
protect
diseas
prevent
provid
tabl
although
antibodi
respons
good
correl
protect
alway
reflect
avail
protect
mechan
provid
welldifferenti
immun
respons
case
correl
avail
clear
presenc
neutral
vaccinederiv
antibodi
reduc
mucos
viru
replic
viru
shed
viremia
kitten
vaccin
modifi
live
felin
herp
vaccin
howev
regul
cellular
respons
requir
control
tissu
damag
reactiv
diseas
case
antibodi
may
protect
correl
infect
cellular
immun
protect
correl
diseas
abil
modifi
live
vaccin
gener
rapid
onset
cytokin
interferon
rapid
antigen
focus
dendrit
cell
lymphoid
tissu
associ
rapid
onset
protect
even
though
antibodi
respons
may
detect
serum
week
therefor
earli
respons
multipl
cytokin
concurr
activ
innat
immun
system
may
serv
earli
correl
protect
also
document
case
function
immun
outlast
detect
circul
antibodi
true
mani
herpesviru
infect
howev
presenc
detect
neutral
serum
antibodi
correl
protect
recrudesc
diseas
situat
vaccin
anim
may
expos
heterotyp
virus
bacteria
presenc
immun
cell
specif
conserv
antigen
may
import
protect
possibl
effect
mechan
develop
protect
associ
vaccin
may
specif
natur
diseas
infecti
process
recent
studi
provid
import
inform
regard
phenomenon
common
hypothesi
vaccineinduc
immun
reflect
convalesc
immun
follow
natur
infect
exampl
known
recoveri
primari
poxviru
infect
requir
robust
cytokin
respons
natur
killer
cell
antibodi
well
helper
cytotox
lymphocyt
effector
function
howev
recoveri
secondari
infect
requir
tand
blymphocyt
interact
anamnest
antibodi
respons
neutral
antibodi
reduc
infect
viremia
spread
viru
may
extent
block
infect
tcellmedi
respons
allow
surviv
recoveri
seem
clear
balanc
antibodi
cellular
respons
necessari
complet
protect
infect
diseas
well
spread
anim
mention
antigenbind
antibodi
protect
case
influenza
viru
canin
distemp
viru
herpesviru
vaccin
nonneutr
antibodi
may
produc
contribut
block
infect
enhanc
clearanc
infecti
agent
reason
correl
surrog
protect
link
protect
mechan
done
retrospect
analysi
data
efficaci
immunogen
studi
associ
studi
immun
popul
primari
vaccin
efficaci
studi
veterinari
vaccinolog
realiz
signific
success
affect
human
anim
wellb
abil
coexist
virtual
elimin
canin
rabi
north
america
western
europ
indirectli
led
humananim
bond
intim
level
feasibl
canin
rabi
rel
common
howev
remain
mani
diseas
efficaci
effect
vaccin
exist
mani
parasit
diseas
well
diseas
chronic
intracellular
natur
cover
avail
vaccin
case
safeti
profil
efficaci
characterist
exist
vaccin
accept
fortun
promis
technolog
may
close
technic
gap
prevent
challeng
diseas
process
absorpt
antigen
chemic
inactiv
toxoid
virus
aluminum
gel
creation
waterinoil
emuls
antigen
particl
princip
method
use
veterinari
vaccin
formul
case
compound
crude
purifi
saponin
quil
squalen
pluron
block
copolym
ad
enhanc
immun
stimul
although
practic
success
newer
technolog
cpg
dna
defens
peptid
imidazoquinolon
polyphosphazen
may
enhanc
safeti
vaccin
veterinari
medicin
efficaci
addit
cholesterol
phospholipid
may
combin
antigen
saponin
creat
immunostimul
complex
iscom
particl
similar
adjuv
particl
gener
antigen
iscomatrix
admix
directli
antigen
suspens
advanc
formul
may
use
provid
effici
adjuv
turn
allow
develop
microvolum
formul
well
transderm
applic
also
better
understand
immun
genotyp
phenotyp
anim
popul
emerg
individu
formul
vaccin
may
develop
produc
may
enhanc
safeti
efficaci
proteom
technolog
may
well
provid
method
identifi
antigen
subset
among
complex
organ
infecti
agent
bacteria
protozoa
organ
contain
larg
complex
genom
antigen
express
often
depend
growth
condit
medium
may
complex
condit
difficult
reproduc
regul
vitro
combin
transcript
proteom
analysi
may
provid
mean
identifi
key
antigen
associ
tissu
cellular
persist
potenti
virul
analys
could
provid
mean
simplifi
vaccin
formul
includ
protect
antigen
reduc
presenc
nonprotect
potenti
interf
bacteri
protein
would
potenti
improv
efficaci
could
also
improv
safeti
profil
reduc
antigen
mass
vaccin
dose
continu
use
altern
express
system
mani
potenti
advantag
transgen
express
protein
antigen
plantbas
system
may
provid
access
oral
vaccin
well
enhanc
stabil
antigen
express
antigen
avirul
virus
bacteria
yeast
insect
cell
may
provid
manufactur
user
safeti
elimin
need
use
virul
partial
virul
microb
provid
immun
develop
nucleic
acid
vaccin
may
provid
even
greater
formul
simplic
biosecur
viral
particl
capsid
avirul
virus
may
serv
build
block
deliv
nucleic
acid
protein
subunit
antigen
microadjuv
directli
secondari
lymphoid
tissu
would
biolog
engin
vaccin
provid
target
immun
elimin
need
work
danger
microb
like
would
reduc
time
requir
onset
immun
excel
safeti
characterist
one
press
problem
associ
manufactur
vaccin
requir
rapidli
modifi
antigen
formul
new
diseas
emerg
older
pathogen
mutat
reemerg
transcriptom
proteom
combin
establish
recombin
synthet
approach
could
potenti
provid
antigen
could
rapidli
formul
approv
newgener
adjuv
produc
novel
efficaci
vaccin
technolog
commonplac
experiment
laboratori
use
combin
proteom
revers
genet
recombin
molecular
synthes
stabl
consist
adjuv
platform
allow
develop
first
line
defens
vaccin
rapidli
emerg
diseas
short
time
useinspir
approach
vaccin
would
allow
use
assemblylin
techniqu
manufactur
vaccin
new
antigen
requir
could
select
evalu
produc
short
period
time
insert
directli
establish
product
system
process
would
greatli
reduc
time
requir
exploratori
research
earli
develop
classic
develop
cycl
may
requir
year
sometim
may
requir
even
longer
time
unusu
new
type
pathogen
microb
reduct
develop
time
may
achiev
use
newer
research
develop
technolog
clear
new
method
assess
efficaci
definit
direct
correl
immun
also
need
identifi
also
clear
use
mani
new
technic
achiev
discoveri
requir
advanc
regulatori
framework
ensur
effici
adequ
evalu
new
biolog
vaccin
develop
face
mani
technic
polit
ethic
challeng
histori
vaccin
research
develop
well
continu
use
immun
princip
method
prevent
infecti
diseas
predict
innov
experiment
procedur
today
lead
common
clinic
applic
tomorrow
